Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents

Molecular Cancer Therapeutics

Volumn 3, Issue 11, 2004, Pages 1375-1383

  Gourdeau, Henriette ^a   Leblond, Lorraine ^a   Hamelin, Bettina ^a   Desputeau, Clemence ^a   Dong, Kelly ^a   Kianicka, Irenej ^a   Custeau, Dominique ^a   Boudreau, Chantal ^a   Geerts, Lilianne ^a   Cai, Sui Xiong ^b   Drewe, John ^b   Labrecque, Denis ^a   Kasibhatla, Shailaja ^b   Tseng, Ben ^b  

^a Shire Canada   (Canada)

^b Maxim Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (3 BROMO 4,5 DIMETHOXYPHENYL) 3 CYANO 4H CHROMENE DERIVATIVE; ANTINEOPLASTIC AGENT; CHROMENE DERIVATIVE; CISPLATIN; COLCHICINE; MX 116214; MX 116407; MX 126303; MX 58151; MX 58276; MX 76747; N ACETYLCOLCHINOL PHOSPHATE; TUBULIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING SITE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MICROTUBULE ASSEMBLY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

AMINATION; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; BROMINE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MICE; NECROSIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 9444265410     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Cai SX, Nguyen B, Jia S, et al. Discovery of substituted N phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay. J Med Chem 2003;46:2474-81.
2. Cai SX, Zhang HZ, Guastella J, et al. Design and synthesis of rhodamine 110 derivative and caspase-3 substrate for enzyme and cell-based fluorescent assay. Bioorg Med Chem Lett 2001;11:39-42.
3. Zhang HZ, Kasibhatla S, Wang Y, et al. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg Med Chem 2004;12:309-17.
4. Kasibhatla S, Gourdeau H, Meerovitch K, et al. Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity. Mol Cancer Ther 2004;3:1365-73.
5. Ben-Ze'ev A. Cell shape, the complex cellular networks, and gene expression. Cytoskeletal protein genes as a model system. Cell Muscle Motil 1985;6:23-53.
6. Bernal SD, Stahel RA. Cytoskeleton-associated proteins: their role as cellular integrators in the neoplastic process. Crit Rev Oncol Hematol 1985;3:191-204.
7. Thyberg J, Moskalewski S. Microtubules and the organization of the Golgi complex. Exp Cell Res 1985;159:1-16.
8. Rowinsky E, Donehower R, editors. Antimicrotubule agents. Philadelphia: Lippincott-Raven Publishers; 1997. p. 467-83.
9. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997;48:353-74.
10. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998;10:123-30.
11. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anti-Canc Agents 2002;2:1-17.
12. Hadfield JA, Ducki S, Hirst N, McGown AT. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 2003;5:309-25.
13. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17:1061-70.
14. Li Q, Sham H. Discovery and development of antimitotic agents that inhibit tubulin polymerization for the treatment of cancer. J Clin Oncol 2002;17:1061-70.
15. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991;27:482-7.
16. Marx M. Small-molecule, tubulin-binding compounds as vascular targeting agents. Expert Opin Ther Patents 2002;12:769-76.
17. Griggs J, Metcalfe JC, Hesketh R. Targeting tumor vasculature: the development of combretastatin A4. Lancet Oncol 2001;2:82-7.
18. Micheletti G, Poli M, Borsotti P, et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 2003;63:1534-7.
19. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62:7247-53.
20. Chen TR. In situ detection of Mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 1977; 104:255-62.
21. Rowland M, Tozer TN. In: Rowland M, Tozer TN, editors. Clinical pharmacokinetics: concepts and application. Philadelphia: Lae & Febiger; 1989. p. 9-100.
22. Tufto I, Rofstad EK. Transient perfusion in human melanoma xenografts. Br J Cancer 1995;71:789-93.
23. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
24. Plowman J, Dykes D, Hollingshead, M, Simpson-Herren L, Alley MC. In: Teicher B, editor. Anticancer drug development guide: preclinical screening, clinical trials, and approval. Totowa (NJ): Humana Press Inc; 1997. p. 101-25.
25. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-31.
26. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-5.
27. Hotchkiss KA, Ashton AW, Mahmood R, et al. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 2002;1:1191-200.
28. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999;81:1318-27.
29. Blakey DC, Westwood FR, Walker M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002;8:1974-83.
30. Dark GG, Hill SA, Prise VE, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-34.
31. Nihei Y, Suzuki M, Okano A, et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 1999;90:1387-95.
32. Otani M, Natsume T, Watanabe JI, et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 2000;91:837-44.
33. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61:711-6.
34. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16.
35. Lin CM, Ho HH, Pettit GR, Hamel E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989;28:6984-91.